A population-based study of antipsychotic prescription trends in children and adolescents in British Columbia, from 1996 to 2011

Canadian Journal of Psychiatry

Volumn 58, Issue 6, 2013, Pages 361-369

  Ronsley, Rebecca ^a   Scott, David ^b   Warburton, William P ^b   Hamdi, Ramsay D ^b   Louie, Dianna Clare ^c   Davidson, Jana ^c,d   Panagiotopoulos, Constadina ^c,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b Enterprise Economic Consulting Ltd   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^e BC CHILDREN S HOSPITAL   (Canada)

Author keywords

Adolescents; Antipsychotics; Children; Prescribing

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANADA; CHILD; CHILDHOOD DISEASE; DEPRESSION; FEMALE; GENERAL PRACTITIONER; HUMAN; HYPERKINESIA; ICD-9; MAJOR CLINICAL STUDY; MALE; NEUROSIS; PEDIATRICIAN; PRESCHOOL CHILD; PRESCRIPTION; PREVALENCE; SCHOOL CHILD;

EID: 84879637842     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371305800608     Document Type: Article

References (21)

1. Verdoux H, Tournier M, Begaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand. 2010; 121(1):4-10.
2. Olfson M, Blanco C, Liu L., et al National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006; 63(6):679-685.
3. Rani F, Murray ML, Byrne P.J., et al Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics. 2008; 121(5):1002-1009.
4. Shirzadi AA, Ghaemi SN Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry. 2006; 14(3):152-164.
5. Panagiotopoulos C, Ronsley R, Elbe D., et al First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry. 2010; 19(2):124-137.
6. Alessi-Severini S., Biscontri RG, Collins D.M., et al Ten years of antipsychotic prescribing to children: a Canadian population-based study. Can J Psychiatry. 2012; 57(1):52-58.
7. Correll CU, Manu P, Olshanskiy V., et al Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009; 302(16):1765-1773.
8. Panagiotopoulos C, Ronsley R, Kuzeljevic B., et al Waist circumference is a sensitive screening tool for assessment of metabolic syndrome risk in children treated with second-generation antipsychotics. Can J Psychiatry. 2012; 57(1):34-44.
9. Pinhas-Hamiel O., Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet. 2007; 369(9575):1823-1831.
10. Berenson GS, Srinivasan SR, Bao W, et al Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998; 338(23):1650-1656.
11. Lorenzo C, Williams K, Hunt K.J., et al The National Cholesterol Education Program-adult treatment panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007; 30(1):8-13.
12. Wilson PW, D'Agostino RB, Parise H, et al Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005; 112(20):3066-3072.
13. Resnick HE, Jones K, Ruotolo G., et al Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care. 2003; 26(3):861-867.
14. Alessi-Severini S., Biscontri RG, Collins D.M., et al Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996-2006. Psychiatr Serv. 2008; 59(5):547-553.
15. O'Reilly D.J., Goeree RA, Tarride J.E., et al The unintended (and costly) effects due to the introduction of an unrestricted reimbursement policy for atypical antipsychotic medications in a Canadian public prescription drug program: 1996/97 to 2005/06. Can J Clin Pharmacol. 2009; 16(2):e346-e359.
16. Pringsheim T, Panagiotopoulos C, Davidson J., et al Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry. 2011; 20(3):218-233.
17. BC Statistics. Population estimates [Internet]. Victoria (BC): BC Statistics; 2012 [cited 2012 Nov 19]. Available from: http://www.bcstats.gov.bc. ca/StatisticsBySubject/Demography/PopulationEstimates.aspx.
18. Cooper WO, Hickson GB, Fuchs C, et al New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med. 2004; 158(8):753-759.
19. Aparasu RR, Bhatara V. Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004. Curr Med Res Opin. 2007; 23(1):49-56.
20. Curtis LH, Masselink LE, Ostbye T, et al Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States. Arch Pediatr Adolesc Med. 2005; 159(4):362-366.
21. Cooper WO, Arbogast PG, Ding H, et al Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr. 2006; 6(2):79-83.